Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News MetaVia Inc MTVA

Healthcare Biotechnology
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor... see more

Current News (NDAQ:MTVA)

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

PR Newswire 9 days ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire 10 days ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

PR Newswire 12 days ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

PR Newswire October 27, 2025

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

PR Newswire October 20, 2025

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

PR Newswire October 14, 2025

MetaVia to Present at Upcoming Investor and Industry Conferences

PR Newswire August 26, 2025

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire August 7, 2025

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

PR Newswire August 6, 2025
View More News ››

Opinion & Analysis (NDAQ:MTVA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MTVA)

NRBO.....low vol on NR this a.m

On watch
Iseneschal - March 13, 2024

NRBO .... Heads up ; )

A break of $1.65 could be meaningful
Iseneschal - November 23, 2022

NRBO...... On watch

Nice volume .....it just needs some Price action Coin toss
Iseneschal - November 23, 2022

NRBO ..... BTFD anyone ?

Or am I the only one with the cajoles ???  LMFAO
Iseneschal - November 10, 2022

NRBO ..... Well Folks... Guess what?

I'm f'king right again .......LMFAO And all u peeps can't even take 2 f'king seconds to like my posts What ever !
Iseneschal - November 9, 2022

NRBO ....early a.m runner in the pre market open ; )

Traded as high as $1.80 Lets see if this turns out to be a major move to fill that 2nd gap I previously mentioned or its just another...
Iseneschal - November 9, 2022
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »